See-Saw: Challenger Natco Is Now Licensee For Lilly’s Baricitinib

 
• By Anju Ghangurde

Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?

see-saw
Lilly ropes in Natco as licensee for baricitinib • Source: Alamy

More from India

More from Focus On Asia